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Research
Exposure to environmental pollutants, such 
as cigarette smoke, has been associated with 
increased susceptibility to influenza infec-
tions. Specifically, epidemiologic studies show 
that smokers are more susceptible to influenza 
virus infections than are nonsmokers (Arcavi 
and Benowitz 2004; Kark and Lebiush 1981), 
but the mechanisms mediating this effect are 
not clear. In mice, chronic exposure to main-
stream cigarette smoke can alter influenza 
virus–induced primary antiviral and inflam-
matory responses, but adaptive immune 
responses, as marked by influenza-specific 
antibody production, appear to be unaffected 
(Robbins et al. 2006). Similarly, an influenza 
outbreak in the Israeli army demonstrated 
that smokers were more susceptible to influ-
enza virus infections than were nonsmokers, 
but influenza-specific antibody levels were not 
decreased (Kark and Lebiush 1981; Kark et al. 
1982; Lebiush et al. 1982). Thus, available 
evidence suggests that the effects of cigarette 
smoke on susceptibility to influenza infection 
may involve elements of early or innate host 
defense against viruses.
Our goal is to understand the clinically 
relevant mechanisms by which exposure to 
cigarette smoke and other airborne pollut-
ants affect susceptibility and response to 
viral respiratory infections in humans. We 
therefore sought to develop a protocol for 
the study of human airway responses to 
virus in the intact human respiratory tract. 
Nasal delivery of live attenuated influenza 
virus (LAIV) vaccine induces the full range 
of host immune responses similar to a natu-
ral influenza infection without inducing 
serious adverse effects (Boyce et al. 1999; 
Hammitt et al. 2009; Maassab and Bryant 
1999) and therefore is a potentially useful 
tool to study influenza infections in humans 
in vivo. Using commercially available LAIV, 
we aimed to develop a protocol to test how 
cigarette smoke exposure alters inflamma-
tory and antiviral responses to influenza in 
the human respiratory tract. To address this 
objective, we serially sampled nasal secretions 
in an observational cohort study comparing 
local nasal mucosal responses to LAIV among 
healthy young adults who are active smokers, 
nonsmokers exposed to secondhand smoke 
(SHS), and unexposed controls.
Materials and Methods
Study subjects. Subjects were healthy young 
adults 18–35 years of age in three groups: 
a) nonsmokers not regularly exposed to SHS 
(control group); b) nonsmokers self-described 
as routinely exposed to SHS in their home, 
workplace, or social settings (SHS group); 
and c) self-described active cigarette smok-
ers (smoker group). Exclusion criteria were 
history of asthma, chronic obstructive pul-
monary disease, cardiac disease, or any 
chronic cardiorespiratory condition; any type 
of immunodeficiency; prior known illness 
diagnosed specifically as influenza; current 
pregnancy; or egg allergy. The screening pro-
tocol included specific testing to rule out 
HIV infection and pregnancy. Subjects were 
not screened for the presence of influenza-
specific antibodies. However, subjects who 
had received influenza vaccine with the same 
antigenic composition (either attenuated or 
killed) in the prior 12 months were excluded. 
Informed consent was obtained from all sub-
jects, and the protocol was approved by the 
University of North Carolina at Chapel Hill 
Biomedical Institutional Review Board.
Study design and sample estimate. This 
was a prospective observational cohort study 
comparing nasal responses (virus quantity, 
host defense factors) to standard doses of 
LAIV in individuals with varying exposures 
to tobacco smoke. Baseline measurements 
were done at a screening visit, on day –3, and 
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Ba c k g r o u n d: Epidemiologic evidence links tobacco smoke and increased risk for influenza in 
humans, but the specific host defense pathways involved are unclear.
oB j e c t i v e: We developed a model to examine influenza-induced innate immune responses in 
humans and test the hypothesis that exposure to cigarette smoke alters nasal inflammatory and anti-
viral responses to live attenuated influenza virus (LAIV).
Me t h o d s : This was an observational cohort study comparing nasal mucosal responses to LAIV 
among young adult active smokers (n = 17), nonsmokers exposed to secondhand smoke (SHS; 
n = 20), and unexposed controls (n = 23). Virus RNA and inflammatory factors were measured in 
nasal lavage fluids (NLF) serially after LAIV inoculation. For key end points, peak and total (area 
under curve) responses were compared among groups.
re s u l t s: Compared with controls, NLF interleukin-6 (IL-6) responses to LAIV (peak and total) 
were suppressed in smokers. Virus RNA in NLF cells was significantly increased in smokers, as 
were interferon-inducible protein 10:virus ratios. Responses in SHS-exposed subjects were generally 
intermediate between controls and smokers. We observed significant associations between urine 
cotinine and NLF IL-6 responses (negative correlation) or virus RNA in NLF cells (positive correla-
tion) for all subjects combined.
co n c l u s i o n s: Nasal inoculation with LAIV results in measurable inflammatory and antiviral 
responses in human volunteers, thus providing a model for investigating environmental effects on 
influenza infections in humans. Exposure to cigarette smoke was associated with suppression of 
specific nasal inflammatory and antiviral responses, as well as increased virus quantity, after nasal 
inoculation with LAIV. These data suggest mechanisms for increased susceptibility to influenza 
infection among persons exposed to tobacco smoke.
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on day 0. Subjects received a standard nasal 
inoculum of LAIV (FluMist; MedImmune, 
Gaithersburg, MD; administered by study 
nurse according to manufacturer’s instruc-
tions) in both nostrils on day 0 and then 
returned at intervals (days 1, 2, 3, 4, and 9) 
for repeat nasal lavages. Subject exposure his-
tory questionnaires and urine cotinine levels 
were used to estimate cigarette smoke expo-
sure. Subjects were asked to avoid the use of 
anti-inflammatory medications such as non-
steroidal anti-inflammatory drugs during their 
participation in the study, and no subjects 
reported using these drugs during the study.
Because no prior similar study existed for 
preliminary data, a sample estimate for the 
study was based on preliminary data for the 
magnitude and variation in effects of chronic 
tobacco smoke exposure on responses to influ-
enza virus by epithelial cells cultured in vitro 
from the nasal passages of smokers and non-
smokers in our laboratory. These data sug-
gested that a sample of 20 subjects per group 
would yield 80% power to detect a doubling 
of virus quantity due to tobacco smoke expo-
sure, with two-sided α = 0.05. A dropout rate 
of 20% was anticipated, so the final enroll-
ment target was 25 per group.
Nasal lavage. Nasal lavage was carried out 
using a method previously described (Noah 
and Becker 2000) by repetitive spraying of 
sterile normal saline irrigation solution (4 mL 
total) into the nostril, followed by volun-
tary expelling of fluid by the subject into a 
specimen collection cup. Both nostrils were 
lavaged in this way, and the resulting nasal 
lavage fluid (NLF) from both sides was com-
bined. Cytocentrifuge slides were prepared, 
fixed, and stained using modified Wright stain 
for differential cell counts by microscopic 
evaluation of 200 consecutive cells at high 
magnification. The remainder of the NLF 
was centrifuged at 500g × 7 min to remove 
cells and debris, and the cell-free supernatant 
was stored in aliquots at –80°C until used in 
mediator assays. The NLF cell pellet was pro-
cessed for total RNA as described below, for 
use in virus quantitation.
Quantitation of influenza virus. The LAIV 
vaccine contained three component strains 
(influenza A H3N2, influenza A H1N1, and 
influenza B), which were modified to corre-
spond to predicted prevalent strains each year. 
Between the 2 years during which this study 
was carried out, only the H1N1 strain was 
modified. We quantified influenza virus in 
RNA derived from pelleted NLF cells using 
quantitative reverse-transcription polymerase 
chain reaction (qRT-PCR), as described 
previously (Hammitt et al. 2009). The viral 
target sequence chosen for primers was influ-
enza B hemagglutinin-A (HA), because the 
influenza B component of the LAIV vac-
cine (B/Malaysia/2506/2004) remained 
unchanged during the 2 years the study was 
conducted, and because this sequence was 
more easily detectable than was the H3N2   
(A/Wisconsin/67/2005) HA.
Total RNA was extracted from NLF cells 
using TRizol (Invitrogen, Camarillo, CA) fol-
lowing the supplier’s instructions. First-strand 
cDNA synthesis and qRT-PCR were per-
formed as described previously (Ciencewicki 
et al. 2007). The RNA analyses were per-
formed using primer and probe sets designed 
to detect influenza B/Malaysia/2506/2004 
HA gene (GenBank accession no. EU124275) 
(Custom TaqMan gene expression assays; 
Applied Biosystems, Foster City, CA) and 
commercially available primers and probes to 
detect β-actin mRNA (Inventoried TaqMan 
gene expression assays; Applied Biosystems). 
HA RNA levels were expressed as a ratio to 
β-actin mRNA levels to normalize for cDNA 
input. According to standardized real-time 
PCR protocols, samples were considered to 
be “undetermined” if the amplified product 
did not cross a preset threshold after 40 PCR 
cycles, indicating insufficient template cDNA.
Mediator assays. Interleukin (IL)-6, 
interferon-inducible protein 10 (IP-10), and 
IL-8 in NLF were quantified using specific 
commercial enzyme-linked immunosorbent 
assay (ELISA; R&D, Minneapolis, MN) 
according to manufacturer instructions. 
Myeloperoxidase was also measured using 
specific commercial ELISA (Assay Designs, 
Ann Arbor, MI). In all cases, standard curve 
r2 > 0.98, and out-of-range samples were 
diluted and reassayed. Additionally, for sam-
ples with sufficient volume remaining, a panel 
of cytokines was assayed using a multiplex 
ELISA platform (Human Pro-Inflammatory 
9-Plex; Meso Scale Discovery, Gaithersburg, 
MD) according to manufacturer instructions. 
Urine cotinine was measured by ELISA (Bio-
Quant, Inc., San Diego, CA) and expressed 
as a ratio to creatinine, measured by a colori-
metric assay (Oxford Biomedical Research, 
Rochester Hills, MI).
Statistical analysis. The main nasal 
response outcome measures were inflam-
matory mediators and virus quantity. For 
descriptive purposes, unadjusted levels of 
mediators were reported at each time point 
for each study group. Data were also analyzed 
as ratio to baseline (day 0) at each time point 
to describe response magnitudes. For statisti-
cal comparisons among groups, data for each 
subject were expressed as peak response (max-
imum ratio to baseline after LAIV inocula-
tion) and total response [ratio to baseline area 
under curve (AUC) after LAIV inoculation]. 
Mann–Whitney tests were used for inter-
group comparisons, or Kruskal–Wallis one-
way analysis of variance was used for multiple 
comparisons. GraphPad Prism was used for 
all statistical calculations other than AUC, for 
which we used SAS (version 9.2; SAS Institute 
Inc., Cary, NC). 
Results
Subject characteristics. Table 1 shows demo-
graphic and smoke exposure characteristics 
of the subjects completing the study. Three 
of 26 enrolled subjects in the control group, 
4 of 24 in the SHS group, and 4 of 21 in the 
smoker group dropped out before completion 
of the protocol. For the subjects completing 
the protocol, the groups did not differ sig-
nificantly for age or body mass index (BMI). 
Smokers had a higher proportion of females 
than the other two groups, but this was not 
statistically significant. Mean self-reported 
daily exposures, self-reported active smoking 
history, and urine cotinine levels during the 
study period all followed the expected pat-
terns for the three groups, suggesting that 
subjects’ group classifications at entry into 
the study were accurate with regard to their 
exposures to tobacco smoke. No serious 
adverse events occurred among subjects who 
completed the protocol. Five minor adverse 
events were recorded, consisting of one con-
trol subject with gastrointestinal symptoms 
on day 5 (a non-visit day); one SHS subject 
with vomiting on day 2 and hypertension 
(blood pressure > 140/90, thought likely due 
to high caffeine intake) on days 3 and 4; one 
smoker with nausea, slight headache, and 
light  headed  ness on day 0; one smoker with 
transient fevers and chills on day 6; and one 
smoker with nausea on days 1 and 2.
Time course of response to LAIV. We ini-
tially characterized the time course of nasal 
innate host defense factor responses to LAIV 
Table 1. Subject characteristics and indices of tobacco smoke exposure.
Parameter Controls (n = 23) SHS (n = 20) Smokers (n = 17)
Age (years) 24.4 ± 0.7 (19–30) 23.7 ± 1.0 (19–33) 23.9 ± 1.0 (18–35)
Sex (n; female/male) 11/12 9/11 11/6
BMI 23.7 ± 0.7 (19.3–32.6) 25.8 ± 1.0 (18.7–35.1) 24.2 ± 1.1 (18.9–35.5)
SHS exposurea 0.4 ± 0.1 (0.0–3.1) 8.1 ± 2.7# (0.2–54.1) 6.6 ± 1.5# (0.2–20.5)
Cigarettes smokedb NA NA 10.7 ± 2.2 (0.0–37.2)
Urine cotininec 0.9 ± 0.8 (0.0–19.5) 2.4 ± 1.7 (0.0–34.7) 26.4 ± 7.1# (2.7–116.8)
NA, not applicable. Data are mean ± SE (range) except where otherwise indicated.
aEstimated secondhand cigarettes exposed to per day, averaged from each subject’s self-reported estimates for study 
days –3 through 21. bCigarettes smoked per day, averaged from each subject’s self-reported estimates for study days –3 
through 21. cng creatinine (× 100)/mg creatinine, averaged from each subject’s urine measurements on study days 0–4. 
#p < 0.001 vs. control, Kruskal–Wallis test with Dunn’s posttest.Noah et al.
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in healthy, nonsmoking controls. Figure 1 
summarizes the time courses for virus quan-
tity and cytokines. Virus quantity as meas-
ured by influenza B HA RNA in NLF cells 
tended to peak on day 1 after LAIV inocu-
lation and declined to near zero by day 4. 
Figure 1 and Supplemental Material Table 1 
(doi:10.1289/ehp.1002258) summarize lev-
els of the inflammatory factors measured at 
baseline and on each day after LAIV inocula-
tion in the controls. Of the cytokines meas-
ured, only IL-6, IP-10, and interferon (IFN)-γ 
showed statistically significant increases after 
LAIV inoculation. (For IFNγ, the Kruskal–
Wallis p-value was 0.03, although posttests 
did not show p < 0.05 for any individual day 
vs. day 0.) Medians for these three cytokines 
tended to peak on days 2–3 after inoculation 
and then declined back toward baseline levels 
by day 9. Although some individuals showed 
what appeared to be responses above baseline 
for some of the other cytokines measured, in 
aggregate we found no statistically significant 
increase for IL-1β, IL-2, IL-8, IL-10, tumor 
necrosis factor-α (TNFα), or granulocyte 
macrophage colony-stimulating factor. Levels 
of IFNα and IFNβ were undetectable in NLF. 
We additionally assessed percent neutrophils 
and myeloperoxidase levels in NLF. Neither of 
these indicators of neutrophil response showed 
statistically significant increases after LAIV [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.1002258)]. Thus, although the overall 
inflammatory response to the low-level infec-
tion induced by LAIV appears to be minimal 
immediately after inoculation in healthy, non-
smoking young adults, we observed significant 
upregulation of several specific mediators of 
inflammatory (IL-6), antiviral (IP-10), and 
immune response (IFNγ) pathways.
Comparison of responses to LAIV among 
unexposed controls, SHS-exposed nonsmok-
ers, and smokers. For the three cytokines that 
appeared to be clearly increased in NLF after 
LAIV in controls, we compared responses in 
SHS-exposed nonsmokers and active smokers 
with those of controls. For all three cytokines, 
baseline (day 0) levels before LAIV inoculation 
among these populations did not differ signifi-
cantly, although we observed substantial vari-
ability within each group (Table 2). Baseline 
data averaged for the screening visit, day –3, 
and day 0 also did not differ for any end point 
among the groups (data not shown).
Figure 2 shows time courses for IL-6, 
IP-10, and IFNγ for the subject groups. 
Responses to LAIV, as reflected in ratio to 
baseline, tended to be suppressed for all three 
end points in the SHS and especially the 
active smoking group. For intergroup statis-
tical comparisons of responses to LAIV, we 
expressed individual subject data as peak and 
total responses, as described in “Materials and 
Methods.” By these measures, IL-6 responses 
were significantly suppressed in smokers com-
pared with controls. We observed decreased 
median IP-10 and IFNγ responses in smok-
ers as well, although the contrasts were not 
statistically significant (Figure 2, Table 2). 
For IFNγ response to LAIV expressed as 
maximum ratio to baseline, the significantly 
suppressed response for smokers could have 
been driven in part by relatively high base-
line levels among some subjects in this group 
(Table 2), although baseline levels themselves 
were highly variable and did not differ sig-
nificantly among groups (Kruskal–Wallis p = 
0.41). Median peak or total responses of SHS-
exposed subjects were intermediate between 
controls and smokers for all three cytokines.
Virus quantity and its relationship to 
cytokine responses. We quantified virus in 
NLF cells using qRT-PCR for influenza B HA 
RNA sequences as a ratio to β-actin sequences. 
Samples from at least one time point in several 
subjects in each group contained insufficient 
cellular material (ascertained by quantity of 
β-actin) to allow quantitative analysis for virus. 
Additionally, because we used NLF samples 
from the first seven control subjects studied 
in multiple initial range-finding assays, inad-
equate sample remained for virus quantita-
tion in NLF cells from these subjects. Data 
for virus quantity were thus available for 
15 controls, 16 SHS, and 11 smokers. All data 
described below relate to this subset of subjects 
with quantitative virus data.
HA RNA was undetectable at day 0 base-
line in all subjects except one, who had an 
extremely low but detectable level, and was 
undetectable in all subjects at days 9 and 
21 after inoculation. HA RNA was highest 
on day 1 in all groups, with levels declining 
over the next 3 days; median quantity was 
higher at all times in smokers compared with 
the other groups (Figure 3A). AUC analy-
sis of data for days 0–4 showed significantly 
increased HA RNA in NLF cells for smok-
ers compared with controls (Table 3). The 
SHS group did not differ significantly from 
controls, although AUC results suggested 
an intermediate quantity of virus between 
Figure 1. Time course of influenza virus measured by qRT-PCR as ratio of influenza type B HA RNA to 
β-actin mRNA in NLF cells and cytokines in NLF, after inoculation with LAIV in healthy nonsmoking sub-
jects (controls). Cytokine data are shown as fold change (Δ) from day 0 baseline, to illustrate differential 
responses among the cytokines. GM-CSF, granulocyte macrophage colony stimulating factor. All data 
points are shown as median for study day. IP-10, IL-6, and IFNγ but not other cytokines showed statisti-
cally significant increases (days 2–4) compared with day 0.
5
4
3
2
1
0
12
10
8
6
4
2
0
01234567891 0
Study day
LAIV inoculated
H
A
 
m
R
N
A
 
(
r
a
t
i
o
 
t
o
 
β
-
a
c
t
i
n
 
m
R
N
A
)
N
L
F
 
c
y
t
o
k
i
n
e
 
f
o
l
d
 
Δ
 
(
v
s
.
 
d
a
y
 
0
) IP-10
IL-6
IL-2
IL-8
IL-10
Inﬂuenza
GM-CSF
IFNγ
IL-1β
TNFα
Table 2. Comparison of data for LAIV-induced cytokine increases in NLF among controls, SHS-exposed 
subjects, and active smokers [median (interquartile range)].
Parametera Controls (n = 23) SHS (n = 20) Smokers (n = 17)
IL-6
Baseline 4.5 (1.3–16.1) 5.5 (1.8–13.7) 6.9 (3.8–14.4)
Ratiomax 7.5 (4.7–20.2) 5.4 (1.8–11.2) 2.8* (1.2–8.0)
RatioAUC 37.8 (23.1–70.5) 19.3* (8.0–24.4) 10.0# (5.4–23.2)
IP-10
Baseline 2,592 (844–6,263) 3,527 (1,455–6,269) 2,332 (1,893–3,822)
Ratiomax 9.1 (3.1–22.3) 4.6 (3.3–6.1) 4.2 (2.3–9.8)
RatioAUC 31.2 (12.1–74.5) 21.5 (15.1–42.2) 19.2 (10.2–35.1)
IFNγb
Baseline 5.0 (1.6–84.5) 2.3 (1.1–64.0) 53.4 (2.3–161.4)
Ratiomax 20.8 (3.4–48.2) 6.5 (1.1–21.8) 3.0* (1.0–10.5)
RatioAUC 64.5 (9.8–154.5) 32.9 (11.5–93.7) 14.1 (2.7–33.4)
aBaseline indicates cytokine levels (pg/mL NLF) on day 0 (before LAIV administration). Ratiomax and RatioAUC are the 
ratio to baseline (day 0) maximum value and AUC during days 1–9 after LAIV inoculation.bFor IFNγ measurements, n = 14 
controls, n = 14 SHS, and n = 12 smokers. *p < 0.05, and #p < 0.001, vs. control, Kruskal–Wallis test with Dunn’s posttest.Tobacco smoke and influenza virus
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controls and smokers (Table 3). We observed 
a weak but statistically significant correlation 
of maximum HA RNA with average urine 
cotinine averaged during the study period, for 
the three study groups combined (r2 = 0.15, 
p = 0.01; Figure 3B). We observed a similarly 
significant correlation for HA RNA AUC and 
urine cotinine (r2 = 0.14, p = 0.02).
Because early antiviral and inflamma-
tory mucosal responses might be expected 
to be linked to virus quantity, we calculated 
ratios of IL-6, IP-10, and IFNγ responses 
to virus quantity for each using maximum 
and AUC data for each subject and com-
pared these ratios among the subject groups. 
When cytokine response data were “normal-
ized” to virus quantity in this way, IL-6 and 
IP-10 responses appeared to be suppressed 
in both the SHS and smoker groups com-
pared with controls, whereas IFNγ response 
was suppressed only in smokers  [see 
Supplemental Material, Table 2 (doi:10.1289/
ehp.1002258)].
Year 1 versus year 2 comparisons. The 
study was carried out over a 2-year period, 
from 2006 to 2008. The trivalent LAIV strain 
composition for these 2 years was identical 
for the H3N2-like influenza A component 
(A/Wisconsin/67/2005) and the influenza B 
component (B/Malaysia/2506/2004). However, 
the H1N1 component changed from 
A/New Caledonia/20/99 during 2006–2007 to 
A/Solomon Islands/3/2006 during 2007–2008. 
Furthermore, our subject recruitment success 
during the 2 study years was not symmetric for 
all three study groups. Controls were overrep-
resented during year 1 (controls, n = 20; SHS, 
n = 3; smokers, n = 4), so we preferentially 
recruited smoke-exposed subjects in year 2 
(controls, n = 3; SHS, n = 17; smokers, n = 13). 
For these reasons, we assessed the study year 
effect in our analysis to estimate whether this 
could have accounted for the different results 
among the study groups. We found no dis-
tinct pattern by year, or statistically significant 
differences between study years, for any end 
point (data not shown). Our statistical power 
Figure 2. Time courses of IL-6, IP-10, and IFNγ in NLF after LAIV inoculation: ratio to baseline (day 0). (A–C) Individual subject data. (D–F) Data summarized for 
each study day. Fold Δ, fold change. All data are shown as median at each time point. Broken lines indicate ratio = 1 (no change from baseline). Black line, con-
trols; blue line, SHS exposed; red line, smokers. SHS-exposed group data are omitted from A–C for clarity.
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Figure 3. Influenza type B HA RNA in NLF cells. (A) Time course after LAIV inoculation at day 0 (ratio to 
β-actin). Black line, controls; blue line, SHS exposed; red line, smokers. (B) Relationship between maxi-
mum HA RNA during days 1–4 after inoculation and urine cotinine (ratio to creatinine, averaged over days 
1–4 after inoculation) for each subject. Black dots, controls; blue dots, SHS exposed; red dots, smokers. 
Black line indicates linear regression line calculated for all subjects combined (p = 0.01, r2 = 0.15). 
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Table 3. Comparison of data for influenza B HA RNA quantity (as ratio to β-actin) during study days 1–4 
among controls, SHS-exposed subjects, and active smokers [median (interquartile range)].
Parameter Controls (n = 15) SHS (n = 16) Smokers (n = 11)
Maxday 1–4
a 3.2 (0.5–33.2) 20.9 (4.5–145.1) 96.8* (9.6–265.8)
AUCday 1–4
b 5.1 (0.7–30.5) 21.3 (4.2–138.7) 226.8* (20.2–880.0)
aMaximum HA RNA quantity, day 1–4 after LAIV inoculation. bAUC HA RNA quantity, day 1–4 after LAIV inoculation. 
*p < 0.05 vs. control, Kruskal–Wallis test with Dunn’s posttest.Noah et al.
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to find such differences was low. However, in 
a sufficiently powered mixed model analysis of 
IL-6 and HA RNA data including study year as 
a term in the model, we detected no significant 
year effects (p = 0.61 and 0.47, respectively).
Discussion
Epidemiologic evidence as well as in vitro and 
mouse in vivo data have shown that exposure 
to inhaled toxicants modifies the ability to 
respond to influenza virus infections (Arcavi 
and Benowitz 2004; Robbins et al. 2006; 
Wong et al. 2009). However, establishing 
direct cause-and-effect relationships between 
exposure to inhaled pollutants and altered 
influenza-induced responses is hampered by 
lack of safe models to study influenza infec-
tions in human volunteers. We used inoc-
ulation with LAIV as a model to study the 
effects of cigarette smoke exposure on influ-
enza-induced responses in the nasal mucosa. 
LAIV results in transient viral shedding and 
immune/inflammatory responses similar to 
those observed in naturally acquired influenza 
infections (Zangwill 2003). Our data sug-
gest that LAIV may be a useful tool to study 
the effects of inhaled pollutants on influenza 
infections in human volunteers.
We found that local nasal responses to 
LAIV in healthy young smokers differed from 
those in nonsmokers not exposed to SHS, 
including suppression of a normally robust 
IL-6 response and increased virus quantity. 
In the context of influenza infections, IL-6 is 
a key cytokine important for regulating the 
shift from innate to adaptive components of 
the antiviral immune responses (Jones 2005), 
including proliferation of T cells and influ-
enza-specific memory T cells (Longhi et al. 
2008). Therefore, suppressed induction of IL-6 
expression after infection with influenza could 
have an impact on T cell–dependent adap-
tive immune responses, although we did not 
measure T-cell responses in the present study. 
We also found evidence that IFNγ (“immune” 
interferon) is suppressed in smokers. Our 
study may be the first to directly implicate, 
in human volunteers with a controlled virus 
exposure, specific host defense factors under-
lying the epidemiologic link between tobacco 
smoke exposure and susceptibility to viral 
infections, including influenza.
Nonsmokers exposed regularly to SHS 
also had suppressed total IL-6 responses after 
LAIV and generally appeared to have results 
that were intermediate between controls and 
active smokers. Along with a statistically sig-
nificant correlation between urine cotinine 
levels and virus quantity, this suggests that the 
factors responsible for these changes are pres-
ent in SHS as well as in mainstream cigarette 
smoke. This observational cohort study thus 
suggests that either active or SHS exposures 
to tobacco smoke may have a measurable 
impact on early innate respiratory mucosal 
host defense responses to influenza virus.
Some experimental studies of the impact 
of oxidant pollutants on human respiratory 
epithelium have found a stimulatory effect 
on inflammatory cytokine production (Chan 
et al. 2005; Ciencewicki et al. 2007; Jaspers 
et al. 2005, 2009; Kode et al. 2006; Pace 
et al. 2008). Although some of these data thus 
appear to contrast with our finding of sup-
pressed (not increased) IL-6 levels in nasal 
secretions, it is possible that the predominant 
early producers of IL-6 in respiratory mucosa 
are resident nonepithelial innate host defense 
cells. There is evidence in both animal mod-
els and human studies for cigarette smoke–
induced suppression of some functions of 
these cell types (Lambert et al. 2007; Mehta 
et al. 2008; Mortaz et al. 2009; Robbins et al. 
2006). A common pathophysiologic effect 
of many tobacco smoke components may 
be to increase cellular oxidant stress, which 
can lead to altered host defense and virus 
clearance (Cho et al. 2009). Beyond direct 
effects of tobacco smoke, it is possible that 
inflammatory responsiveness to subsequent 
microbial stimuli could be suppressed after 
prior smoke exposure. Kulkarni et al. (2010) 
recently reported that cigarette smoke extract 
suppressed IL-8 and IL-6 responses of human 
and murine respiratory epithelial cells after 
bacterial stimulation, an effect that was abro-
gated by antioxidants.
Whether exposure to tobacco smoke 
enhances or suppresses virus-induced inflam-
mation may also depend on the virulence, 
chronicity of tobacco smoke exposure, and 
viral dose. For example, Robbins et al. (2006) 
exposed C57BL/6 mice for 3–5 months 
to mainstream tobacco smoke and then to 
influenza A and showed that smoke exposure 
caused suppression of inflammatory responses 
to low-dose influenza in bronchoalveolar 
lavage fluid (neutrophils, mononuclear cells) 
but no change for levels of cytokines IL-6, 
TNFα, or macrophage-inflammatory pro-
tein-2. In contrast, in the case of high-dose 
influenza, smoke exposure was associated with 
heightened IL-6 and TNFα responses. These 
studies suggest that the effect of tobacco 
smoke on host response to influenza is com-
plex and partly dependent on chronicity of 
exposure and on infection dose. Alveolar mac-
rophages from chronically smoke-exposed 
mice had reduced lipopolysaccharide-stim-
ulated cytokine production {IL-6, TNFα, 
RANTES [regulated upon activation, nor-
mal T-cell expressed, and secreted protein, 
also known as chemokine (C-C motif) ligand 
5]}, as well as reduced nuclear translocation 
of nuclear factor-κB and activator protein-1 
(Gaschler et al. 2008). In general, our study’s 
results thus seem to most closely correlate 
with the inflammatory suppression effects 
associated with chronic smoke exposure and 
“low-dose” virus in murine models.
Recent in vitro data from our laboratory 
(Jaspers et al. 2009) suggested that exposure 
to tobacco smoke directly inhibits epithe-
lial antiviral pathways. Type 1 IFNs (IFNα, 
IFNβ) themselves were not detectable in our 
NLF, and neither peak nor total responses of 
the IFN-dependent cytokine IP-10 differed 
significantly among groups. However, median 
IP-10 responses were lower among smoke-
exposed subjects, and the ratio of IP-10 to 
virus quantity, a potential indicator of the 
robustness of antiviral pathway responses, was 
significantly lower in both SHS-exposed sub-
jects and smokers than in unexposed con-
trols. Our previously published in vitro data 
indicated that these effects may be associated 
with epigenetic modification of the interferon 
regulatory factor 7 (IRF7) gene, leading to 
suppressed expression of this key transcription 
factor in the context of a viral infection. We 
observed this effect both in vitro and in nasal 
epithelial cells obtained at pre-LAIV screen-
ing visits from the same cohort studied here, 
which showed suppressed ability to induce 
the expression of IRF7 in nasal epithelial 
biopsies after inoculation with LAIV (Jaspers 
et al. 2009). Expression of IRF7 is critical 
for amplification of the type 1 IFN response 
(Randall and Goodbourn 2008). Thus, it 
is conceivable that suppressed type 1 IFN 
signaling at the level of the nasal epithelium 
contributed to enhanced viral replication in 
smokers and SHS-exposed individuals in the 
studies presented here. Although it is also pos-
sible that smokers shed more viral sequences 
for reasons unrelated to innate immunity (e.g., 
altered mucociliary clearance), we hypothesize 
that increased replication is the mechanism 
here because of the extended time course for 
increased virus in smokers (Figure 3A) and 
our in vitro experience in which replication is 
enhanced (Jaspers et al. 2009).
An interesting finding in our study is 
that not only active smokers but also indi-
viduals exposed to SHS may have altered early 
mucosal response to virus. This was statisti-
cally most strongly indicated by the data for 
IL-6, although data for ratio of IP-10 to virus 
quantity suggested the possibility of other 
quantifiable effects of SHS. These results 
may provide further insight into the biologic 
basis for epidemiologic data linking expo-
sure to ambient airborne particulate pollut-
ants, including passive tobacco smoke, with 
increased incidence of respiratory infection 
especially in children (Henderson 2008; Kum-
Nji et al. 2006). Widespread exposure to a 
factor reducing virus clearance due to altered 
innate immunity may therefore place a large 
segment of the population at increased risk 
for complications of influenza, as well as indi-
viduals with underlying chronic pulmonary Tobacco smoke and influenza virus
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disorders who are already at increased risk. 
During the recent H1N1 pandemic, exposure 
to airborne pollutants has been suggested as a 
potential factor contributing to the disparity 
of H1N1-induced morbidity and mortality 
seen in Mexico and the United States (Noah 
et al. 2009). Thus, investigations of potential 
links between exposure to common air pol-
lutants, such as SHS, particulate matter, or 
urban smog, are important to identify poten-
tial modifiers of host defense responses during 
naturally acquired infections.
We did not systematically gather data 
regarding symptoms, and we observed no 
apparent significant adverse events in the 
study, although several smokers reported 
gastro  intestinal symptoms and one developed 
transient fever and chills. Our study design 
measuring effects of the self-limited infec-
tion with temperature-sensitive LAIV did not 
allow us to directly investigate smoke exposure 
effects in the lower respiratory tract, where 
they could presumably have a more clinically 
important impact. However, it seems reason-
able to hypothesize based on our data that 
tobacco smoke–induced suppression of innate 
host defense pathways that normally limit the 
initial replication of influenza could worsen 
the severity of infection in the lower respi-
ratory tract, especially in individuals with 
chronic pulmonary diseases such as asthma or 
chronic obstructive pulmonary disease. Recent 
whole-genome approaches suggesting simi-
lar smoking-induced gene expression changes 
in the epithelium of nasal and lower airway 
epithelial cells (Sridhar et al. 2008) would be 
consistent with this hypothesis. 
The interactions between air pollutants 
and respiratory virus infections are complex 
and may be significant for the health of both 
normal and diseased populations. For exam-
ple, epidemiologic studies have demonstrated 
that exposure to the oxidant pollutant nitro-
gen dioxide before infection with respiratory 
viruses increases exacerbation of allergic air-
way disease in children (Chauhan et al. 2003), 
and Wong et al. (2009) showed that influenza 
infections could increase mortality in respira-
tory hospitalizations associated with air pol-
lution, especially ozone. These epidemiologic 
studies support the concept that exposures to 
air pollutants modify influenza-induced host 
defense responses, and vice versa. Our data 
support the strategy of using LAIV responses 
to conduct controlled human exposure stud-
ies to better define the mechanisms under-
lying epidemiologic links between influenza 
severity and air pollution.
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